enGene Q3 FY26 net loss widens 12.11% to USD 32.5 million
ENGN•LEGEND trial update planned for 4Q 2026
The company said LEGEND pivotal Cohort 1 previously showed a 54% complete response rate. Updated regulatory endpoint data is planned for 4Q 2026.
Q3 loss widens on higher operating expenses
enGene posted a Q3 net loss attributable to common shareholders of USD 32.5 million, or USD 0.47 a share.
Loss widened from USD 29 million a year earlier on higher operating expenses, which rose 13.58% to USD 34 million.
- R&D spending fell 11.01% to USD 20.09 million.
- G&A costs climbed 88.82% to USD 13.92 million.
- Cash, equivalents and marketable securities totaled USD 266.3 million as of July 31.
